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Background: Plasma interleukin-6 (IL-6) levels increase during liver resection. The source of this IL-6 is
hitherto unclear. It has been demonstrated that the hepatosplanchnic area takes up IL-6 but the role of the
gut and liver is unknown. The aim of the present study was to investigate the role of the gut and liver in
IL-6 homeostasis during liver surgery.
Methods: Before and after partial hepatectomy, IL-6 was measured in blood sampled from the radial
artery, and the hepatic and portal vein. Blood flow was measured to assess IL-6 fluxes (flow times
AV-differences) across the gut, liver and hepatosplanchnic area.
Results: In 22 patients undergoing liver resection, IL-6 release from the gut after transection was 90.9
(30.1) ng/min (P < 0.001), whereas net IL-6 uptake by the liver equalled 83.4 (41.7) ng/min (P < 0.01).
Overall hepatosplanchnic flux was 7.3 (43.5) ng/min after transection and did not differ significantly from
zero. Overall hepatosplanchnic flux was 87.8 (41.5) ng/min in the major resection group and -59.8
(67.5) ng/min in the minor resection group (P < 0.05).
Discussion: The gut releases IL-6 and the liver takes up IL-6 before and after liver resection. The loss
of IL-6 uptake as a result of a small functional remnant liver could lead to higher IL-6 levels after surgery.
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Introduction
Major abdominal surgery such as liver resection is followed by an
inflammatory response, evidenced by increased systemic levels of
pro- and anti-inflammatory cytokines.1–4 Interleukin-6 (IL-6) is
one of the archetypical pro-inflammatory cytokines, which con-
tributes to the acute phase response to injury and infection.5–7
Plasma IL-6 levels after liver resection are generally regarded to
reflect the magnitude of the systemic inflammatory response and
in fact elevated IL-6 levels during and after liver resection have
been found repeatedly.1,8–12 Potential triggers for high IL-6 levels
are ischaemia–reperfusion injury, hepatocyte injury, intestinal
manipulation and demand for liver regeneration.8,9,11,13 Prolonged
and excessive release of IL-6 and other circulating cytokines
after surgery is associated with systemic inflammatory response
syndrome (SIRS) or sepsis.9,10 However, experimental animal
studies have shown that the production of IL-6 is particularly
important after partial hepatectomy and partial portal vein
ligation, as it appears to be crucial in the onset of liver
regeneration.13–15 This shows that IL-6 has beneficial effects such
as the onset of liver regeneration, but on the other hand high levels
of IL-6 are also associated with postoperative sequelae such as
SIRS or sepsis.9,10 Therefore a tight regulation of IL-6 levels
postoperatively is probably needed.
Two studies performed in man showed that the hepatosplanch-
nic organs (comprising mainly the portal drained viscera and the
liver) are responsible for the uptake of endogenously produced
IL-6.16,17 However, the individual role of the gut and liver in deter-
mining systemic IL-6 levels was not analysed in these previous
studies. It has been hypothesized that IL-6 clearance could be a
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specific liver function.16 Therefore, liver resection would affect the
ability of the liver to take up IL-6 from the blood. Knowledge
about the organs involved in IL-6 production and breakdown
becomes pivotal not only for understanding the IL-6 response to
liver surgery but also in the relation to the role of IL-6 in liver
regeneration. The aim of the present study was to investigate
which of the hepatosplanchnic organs are responsible for release
and uptake of IL-6. In addition, the present study also aimed to
investigate IL-6 handling after major vs. minor liver resection.
Methods
Patients
Patients scheduled for a hepatectomy for primary or secondary
malignant tumours in otherwise healthy livers at Maastricht Uni-
versity Medical Centre were eligible for inclusion. The study was
approved by the medical ethical committee of the Maastricht Uni-
versity Medical Centre+ and conducted in accordance with the
revised version of the Declaration of Helsinki (October 2008,
Seoul). All patients gave written informed consent. Patients were
admitted to the hospital 1 day preoperatively and routine blood
tests were performed. Preoperatively, all patients had radial artery
and central venous catheters inserted to monitor arterial and
central venous blood pressure as part of the standard anaesthetic
care.
Surgical procedures
Liver resection was performed as detailed elsewhere.18 A laparo-
tomy was performed by bilateral subcostal incision, followed by
intra-operative ultrasonographic assessment of the liver. Once
resectability had been confirmed, mobilization of the liver was
performed to prepare for hepatic parenchymal transection, which
was undertaken using a Cavitron Ultrasonic Surgical Aspirator
(Valleylab, Tyco healthcare, Boulder, CO, USA). Argon beam
coagulation (Force GSU System; Valleylab, Boulder, CO, USA),
clips and sutures were used for haemostasis. If necessary hepatic
inflow occlusion was applied by tightening a rubber tube around
the entire hepatoduodenal ligament (total Pringle maneuver) or
selectively around the left or right portal pedicle using an extra
Glissonian approach as considered appropriate for the intended
resection.19 Cycles of 15- to 30-min occlusion alternated with
5-min reperfusion were applied. The choice of whether a Pringle
manoeuvre was used or not as well as the type of inflow occlusion
was made according to the surgeon’s preference. Immediately
after liver resection weights of resection specimens were recorded
in the operating theatre.
Blood sampling and processing
Baseline samples were obtained from the arterial line pre-
operatively after induction of anaesthesia. Then, samples were
obtained from the arterial line at predefined time points: after
mobilization of the liver, before and after transection of the liver
and on the first postoperative day (POD). Finally, on the second
and third postoperative day blood was drawn by venepuncture
(the arterial line was routinely removed at day one). Blood was
also drawn from the portal and hepatic vein (from the side of the
liver with no tumour) before and after liver transection, to calcu-
late arterio-venous (AV) differences of IL-6 across the gut, liver
and hepatosplanchnic area (gut + liver). Blood samples were col-
lected in pre-chilled ethylenediaminetetraacetic acid (EDTA)-
containing vacuum tubes (BD vacutainer, Becton Dickinson
Diagnostics, Aalst, Belgium) and kept on ice. Haematocrit was
determined using microcapillaries. Blood was centrifuged in a
pre-chilled centrifuge at 4°C at 2750 g for 15 min. Plasma was
immediately stored at -80°C until analysis. IL-6 levels were
determined using a commercially available enzyme-linked
immunosorbent assay (ELISA) (Hycult Biotechnology, Uden,
the Netherlands). The lower limit of detection for IL-6 was
16 ng/l.
Assessment of IL-6 flux across the gut and liver
Net organ fluxes (flow ¥ arterial – venous concentration differ-
ence) were calculated across the gut, the liver and the
hepatosplanchnic area. In order to calculate organ fluxes, plasma
flows were calculated by correcting blood flow for haematocrit
[plasma flow = blood flow ¥ (1– haematocrit)].Mean plasma flow
in the portal vein and hepatic artery was obtained in a separate
similar series of patients by our group in the recent past.20 These
patients were comparable with patients in the present group with
respect to baseline characteristics and surgical procedures.
Fluxes were calculated as Fgut = portal plasma flow ¥ ([PV]-[A]),
Fsplanchnic = splanchnic plasma flow ¥ ([HV] – [A]), Fliver = Fsplanchnic
- Fgut. Hepatosplanchnic plasma flow was calculated as portal flow
plus hepatic artery flow. In these equations [PV], [A] and [HV]
indicate portal venous, radial artery and hepatic venous plasma
concentrations, respectively, and Fsplanchnic, Fliver, Fgut denote
splanchnic flux, liver flux and gut flux, respectively. Positive fluxes
indicate release, whereas negative fluxes indicate uptake.
Relation between remnant liver volume and systemic
IL-6 level
Total liver volume and tumour volume were determined by
CT-volumetry according to a previously described method.21 In
order to calculate the volume of the resection specimen the actual,
measured resection weight was multiplied by a factor of 1.22.22
This conversion factor accounts for liver density (g/ml) and com-
pensates the unperfused state of the resection specimen. The func-
tional remnant liver volume (RLV) percentage was calculated with
the following formula:
RLV total liver volume resected weight
total liver v
% .[ ] = − ×( )[ ]1 22
olume tumour volume−[ ]×100%
Statistics
All data are expressed as mean (SEM). Fluxes were tested versus
a theoretical mean of zero usingWilcoxon’s signed Rank test. The
following outcome variables were calculated to analyse serial mea-
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surements and compare minor and major resections with respect
to IL-6 handling:23 areas under the curve were calculated from
baseline to IL-6 peak level and from IL-6 peak level to postopera-
tive day 3, according to the trapezoid method. The slope of the rise
in IL-6 levels was calculated by regressing the IL-6 levels at pre-
surgery and the peak response (indicated as Sloperise). The slope of
the decline in IL-6 levels was calculated by regressing IL-6 levels
from peak levels to postoperative day 3 (indicated as Slopedecline).
To compare different subgroups the non-parametric Mann–
Whitney U-test was applied. Correlation was calculated with
Spearman’s test for non-parametric correlations. A multivariable
regression analysis was conducted to explore whether there was an
independent association of the use of the Pringle manoeuvre with
peak IL-6 concentrations. A P-value < 0.05 was considered to
indicate statistical significance. Statistical analysis was performed
using Prism 4.0 for Windows (Graphpad software, Inc., San
Diego, CA, USA).
Results
Patients
Twenty-two patients scheduled for a hepatectomy for primary
(n = 2) or secondary malignant liver tumours (n = 20) were
included. The median age of the patients was 65 years (30–81).
Routine liver tests were within the normal range (Table 1).
Patients underwent liver resection because of colorectal liver
metastases except for two patients who underwent liver resection
for hepatocellular carcinoma and carcinoid tumour, respectively.
Ten patients underwent major liver resections (3 segments) and
12 a minor liver resection (<3 segments). Time required for
mobilisation of the liver was 60 (6) min. Time needed for transec-
tion of the liver was 114 (10) min. Plasma flows in the portal vein
and hepatic artery were 320 (42) ml/min and 110 (23) ml/min,
respectively. Splanchnic plasma flow was calculated to be 430
(47) ml/min.20 In nine patients the liver resection was performed
under a total intermittent Pringle manoeuver and in five patients
the liver resection was performed under a selective intermittent
Pringle manoeuver. The mean period of ischaemia was 18 (2) min
and the period of reperfusion was 5 min. In eight patients no
Pringle manoeuver was used.
Systemic IL-6 level
Arterial IL-6 levels were below the lower limit of detection pre-
operatively. Therefore the cut-off value of the ELISA (16.0 ng/l)
was used. Arterial plasma IL-6 increased markedly during and
after liver surgery. Before the start of the liver transection arterial
IL-6 levels were 73.3 (44.0) ng/l and increased progressively
throughout transection to 528.3 (110.3) ng/l directly after
transection. Eight hours after the start of surgery, arterial IL-6 had
increased further to 1125 (257.0) ng/l (Fig. 1). On postoperative
day 1, IL-6 levels had decreased to 529.4 (114.8) ng/l and a further
decrease to 236.9 (40.4) ng/l and 66.4 (12.7) ng/l was observed on
postoperative days 2 and 3, respectively (Fig. 1).
IL-6 organ fluxes
IL-6 release from the gut (Fgut) before transection was 10.5
(7.8) ng/min (P < 0.01), whereas net IL-6 uptake by the liver (Fliver)
equalled 12.0 (8.4) ng/min (P < 0.01). Overall hepatosplanchnic
flux (Fsplanchnic) was -1.6 (1.2) ng/min before transection and did
not differ significantly from zero.
Table 1 Patient characteristics
Median (range)
Age (years) 65 (41–81)
Gender (male/female) M 12 F 10
Height (m) 1.74 (1.60–1.95)
Weight (kg) 80 (65–106)
Body mass index 26 (23–33)
Colorectal carcinoma n = 20
Hepatocellular carcinoma (HCC) n = 1
Carcinoid n = 1
Right hepatectomy 9
Central hepatectomy 2
Segmentectomy 11
AST (IU/L) 24 (13–46)
ALT (IU/L) 25 (12–55)
LDH (IU/L) 376 (294–529)
Gamma-glutamyl transpeptidase (IU/L) 44 (29–116)
Alkaline phosphatase (IU/L) 91 (59–168)
Bilirubin (mM) 13 (7–37)
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Figure 1 Interleukin-6 (IL-6) levels in patients (n = 22) undergoing
liver resection for primary or secondary tumours in an otherwise
healthy liver, preoperatively, before and after transection, 8 h after
the start surgery and on postoperative day 1, 2 and 3. Data are
means  SEM. *A aignificant difference (P < 0.05) from the baseline
sample. POD, postoperative day
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IL-6 release from the gut (Fgut) after transection was 90.9
(30.1) ng/min (P < 0.001), whereas net IL-6 uptake by the liver
(Fliver) equalled 83.4 (41.7) ng/min (P < 0.01). Overall
hepatosplanchnic flux (Fsplanchnic) was 7.3 (43.5) ng/min after
transection and did not differ significantly from zero (Fig. 2a–b).
Effects of major versus minor liver resection on IL-6
handling
Patients who underwent major liver resection had significantly
greater peak systemic IL-6 levels after resection than those under-
going minor liver resection. The area under the curve for the IL-6
response from baseline to IL-6 peak level and from IL-6 peak level
to postoperative day 3 was significantly greater in the major than
in the minor liver resection group. Sloperise was also significantly
higher in the major than in the minor liver resection group,
whereas Slopedecline did not differ significantly (Table 2, Figs 3 and
4a–c).
Onmultivariable analysis, the use of the Pringle manoeuver was
also an independent predictor of high peak IL-6 levels (P = 0.04).
The extent of the operation (minor versus major resection), when
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Figure 2 Organ fluxes of interleukin-6 (IL-6) before (a) and after (b) transection (n = 22). The gut releases IL-6 and the liver takes up IL-6. The
hepatosplanchnic area flux is close to zero. Data are means  SEM (*P < 0.01, **P < 0.01, ***P < 0.001, §P < 0.01)
Table 2 Interleukin-6 (IL-6) plasma differences between major and minor resection
Minor liver resection Major liver resection P between
groupMean SEM Mean SEM
IL-6 Peak
ng/l
707.7 146.9 1665.0 434.1 0.04
IL-6 AUC presurgery to peak ng/l*hour 3.2*103 1.1*103 7.1*103 1.7*103 0.04
IL-6 AUC peak to POD 3
ng/l*hour
15.4*103 2.7*103 32.4*103 8.0*103 0.03
IL-6 Slope rise
ng/l/hour
62.5 12.8 203.4 59.0 0.02
IL-6 Slope decline
ng/l/hour
-10.6 3.0 -19.2 6.6 ns
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Figure 3 Interleukin-6 (IL-6) levels for minor (n = 10) vs. major (n =
12) liver resections. POD, postoperative day
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corrected for the Pringle manoeuver, was also independently and
significantly related (major versus minor, odds ratio = 1020, con-
fidence interval 233–1808, P = 0.01) with peak IL-6.
IL-6 release from the gut (Fgut) after transection [151.2
(62.0) ng/min] was higher after major compared with minor liver
resection [40.7 (9.4) ng/min] (P = 0.006). IL-6 uptake by the liver
(Fliver) was 63.4 (30.9) ng/min in the major resection group and
100.5 (73.7) ng/min in the minor liver resection group, which was
not significantly different (P = 0.87). Overall hepatosplanchnic
flux (Fsplanchnic) was 87.8 (41.5) ng/min in the major resection
group and -59.8 (67.5) ng/min in the minor resection group
(P < 0.05) (Fig. 5). This indicates net IL-6 release from the
splanchnic area after major resection versus uptake in the minor
resection group.
Relation between remnant liver volume and systemic
IL-6 level
Mean total liver volume in the whole group (n = 22) was 1837 
101 ml and mean tumour volume was 23  10 ml. Total func-
tional liver volume (total liver volume – tumour volume) was
1814 104 ml. Resection weight was 522 69 g. After correction
using the previously mentioned conversion factor the volume of
the resection specimen weight was 637  84 ml. The remnant
liver volume was 1199  133 ml. Mean functional remnant
liver volume percentage was 65  5%. There was a significant
correlation between the IL-6 AUC peak to POD3 and the remnant liver
volume (P < 0.05, r = -0.46) (Fig. 6).
Discussion
The present study investigated the contribution of hepatosplanch-
nic organs to the release and uptake of IL-6 in patients undergoing
liver resection. To the best of our knowledge the present study is
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Figure 5 After transection interleukin-6 (IL-6) release from the gut is
significantly higher in the major liver resection group. There is a net
IL-6 release from the hepatosplanchnic area in the major liver resec-
tion group compared with IL-6 uptake in the minor resection group.
Data are means  SEM. *Significant difference (P < 0.05)
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Figure 4 (a) Area under curvepresurgery to peak, (b) area under curvepeak to POD3 and (c) sloperise in patients who underwent major vs. minor liver
resection. Data are means  SEM. *Significant difference (P < 0.05)
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the first in humans to demonstrate that the gut releases IL-6 and
the liver takes up IL-6 before and after liver transection. The IL-6
flux across the hepatosplanchnic area was not significantly differ-
ent from zero in the whole group of minor and major liver resec-
tions before and after liver resection. This suggests that this region
does not in general contribute to systemic elevation of IL-6 levels.
In the group undergoing major liver resection a net release of IL-6
from the splanchnic area was observed after liver resection.
Febbraio et al. used a human physical exercise model showing
that in the physiological situation the hepatosplanchnic organs
took up IL-6 while systemic levels were elevated.16 The authors
assumed that the intact human liver was probably responsible for
this negative IL-6 flux across the hepatosplanchnic area. However,
the previous study did not specify the individual role of the gut
and liver in determining systemic IL-6 levels. The present study
involved patients undergoing liver surgery allowing direct access
to the portal and hepatic vein. Therefore, the role of the liver and
gut in IL-6 metabolism could be studied. IL-6 release from the gut
increased after liver resection. Conversely, the liver took up IL-6 to
the same extent after liver resection and consequently the IL-6
inter-organ balance over the hepatosplanchnic area was
unchanged and remained at zero in the whole group.
Comparison of the major and minor liver resection group
revealed that the gut released significantly more IL-6 in the major
liver resection group after resection. Because liver uptake of IL-6
did not entirely match gut IL-6 release, this led to a net IL-6 release
from the hepatosplanchnic area after major hepatectomy. Eventu-
ally this caused significantly higher systemic IL-6 concentrations
in the major liver resection group. Although these data show that
the gut is responsible for significant IL-6 production, it must be
assumed, also based on the present data that extra-splanchnic
production of IL-6 occurs as well. The difference in IL-6 handling
between major and minor liver resections could most likely be a
consequence of a smaller functional remnant liver volume dimin-
ishing IL-6 uptake capacity in the major liver resection group. In
the present study, a significant correlation between the remnant
liver volume and area under the curve of IL-6 levels confirmed this
association. However, this is only circumstantial evidence for the
hypothesis that the IL-6 uptake capacity of the liver is related to
the size of the remnant liver after liver resection.
The condition of a liver containing (metastatic) tumours can
be different from a normal liver in a physiological condition.
Blood was sampled from the non-tumorous side of the liver and
the (metastatic) liver tumour was probably not producing IL-6
because IL-6 baseline samples were not above the cutoff value of
the ELISA (16 ng/l) in the present patients. In addition, the data
in the current paper regarding the splanchnic fluxes of IL-6 were
comparable to the data given by Febbraio et al.,16 measured in
healthy volunteers, providing circumstantial evidence for the
validity of the present data.
On postoperative days 1, 2 and 3, IL-6 levels were higher in the
major liver resection group. The area under the curve for this
period was significantly different between the two groups.
However, the Slope decline was not different between the two groups.
Thismay have been because of the relatively small group size (type
II error), but there are two other potential explanations. First,
reduced IL-6 levels result from rapidly decreased production from
the gut postoperatively. Second, it is known that in humans there is
a very rapid increase in liver mass and function during the first 7
days after partial hepatectomy. Rapid restoration of liver mass may
compensate any differences in diminished liver function between
the major and minor liver resection group. It is highly likely that
this will not be the casewhen postoperative liver failure occurs.The
Pringlemanoeuvrewas also an independent predictor of high peak
IL-6 levels. This can probably be explained by the fact that the
Pringlemanoeuvre leads to a temporary total or partial abrogation
of IL-6 liver uptake ultimately leading to higher peak IL-6 levels in
the Pringle group compared with the non-Pringle group. In accor-
dancewith the results in the present study,Castell et al. showed that
intravenous injection of radio-actively labelled IL-6 into rats
caused IL-6 to disappear from plasma. This radiolabelled IL-6 was
mostly localized on the surface of the parenchymal liver cells,24
indicating liver uptake.Although thenature of this process requires
further clarification, an explanation for this process may be that
IL-6 is necessary for liver regeneration.14,25 Cressman et al. showed
that IL-6 plays a crucial role in the onset of liver regeneration and in
promoting hepatocyte proliferation in mice after partial hepatec-
tomy.14 Most likely, specific binding of IL-6 to a membrane bound
IL-6 receptor in the hepatocyte or via a soluble IL-6 receptor may
play an important role in inducing liver regeneration.26
Although there appears to be an obvious relation between IL-6
and liver regeneration, the absence of IL-6 merely delays restora-
tion of liver mass and IL-6 does not appear to be the only inducer
of liver regeneration.14 Blindenbacher et al. concluded that the
major role of IL-6 after partial hepatectomy in mice is the induc-
tion of an adaptive response ensuring body homeostasis and sur-
vival.25 In line with this, administration of IL-6 can actually
improve the regenerative response of the liver after acute injury in
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mice.27 In contrast, hyper-IL-6 (agonistic protein consisting of
IL-6 linked the soluble IL-6 receptor) or chronically elevated IL-6
levels are associated with inhibition of liver regeneration after
injury.27,28 Studies have shown that IL-6 acts as a pro-survival
factor of apoptosis-mediated liver injury and that it is mainly the
onset of liver regeneration that plays a role in the inhibition of
hepatocyte apoptosis.29 Based on these observations and also
based on the data of the present study it could be assumed that it
is likely that the liver is not simply clearing IL-6 during liver
resection. On the contrary, IL-6 might play an important role
intracellularly in hepatocytes, not only to activate signal pathways
that induce liver regeneration but also to act as a pro-survival
factor of apoptosis-mediated liver injury.
In the present study itwas observed that the gut is responsible for
IL-6 release during liver surgery. In the major liver resection group
the gut released significantly more IL-6 after resection than in the
minor resection group. These observations suggest that the gut
plays a significant role in the inflammatory response after liver
surgery. Little is known about the role of IL-6 in the intestinal
response to liver surgery or other gut injury. The gut may release
IL-6 as a result of major liver resection compromising the func-
tional integrity of the gut barrier. Wang et al. showed in rats that
bacterial translocation from the gut is caused by intestinal injury
and increased gut capillarypermeability aftermajorhepatectomy.30
On the other hand apoptosis in gastrointestinal epithelium has
been associated with liver surgery as well. Jin et al. showed in mice
that IL-6 plays a crucial regulatory role in in vivo enterocyte
homeostasis.31 IL-6 appears to affect enterocyte apoptotic path-
ways, resulting in increased enterocyte resistance to apoptosis and
oxidative injuries. The exact biological significance of IL-6 as a
pro-survival factor in intestinal apoptosis and apoptosis-mediated
liver injury after liver resection in humans remains unclear.
In conclusion, in the present study it was observed that the gut
releases IL-6 and that the liver takes up IL-6 in humans before and
after liver resection. The loss of IL-6 uptake as a result of small
remnant functional liver volume could lead to higher IL-6 levels
during and after surgery. However, the exact consequences of high
IL-6 levels circulating after liver resection are unknown. The liver
might take up IL-6 in order to regulate IL-6 levels and prevent
excessively elevated systemic IL-6 levels. Equally this uptake may
play a role in liver regeneration.
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